1116463--3/16/2007--ORASURE_TECHNOLOGIES

related topics

{product, liability, claim}

{product, candidate, development}

{product, market, service}

{stock, price, operating}

{property, intellectual, protect}

{acquisition, growth, future}

{customer, product, revenue}

{regulation, change, law}

{regulation, government, change}

{tax, income, asset}

{personnel, key, retain}

{operation, international, foreign}

{operation, natural, condition}

{control, financial, internal}

The Need to Obtain Regulatory Approvals and Respond to Changes in Regulatory Requirements Could Adversely Affect Our Business. The Inability to Extend the Shelf Life of Our OraQuick ADVANCE Test Could Adversely Affect Our Business. Failure to Comply With FDA or Other Regulatory Requirements May Require Us to Suspend Production of Our Products or Institute a Recall Which Could Result in Higher Costs and a Loss of Revenues. Our Ability to Sell Products Could be Affected by Competition From New and Existing Diagnostic Products and by Treatments or Other Non-Diagnostic Products Which May be Developed. Our Research, Development and Commercialization Efforts May Not Succeed and Our Competitors May Develop and Commercialize More Effective or Successful Diagnostic Products. If We Lose Our Key Personnel or Are Unable to Attract and Retain Qualified Personnel as Necessary, Our Business Could be Harmed. Future Acquisitions or Investments Could Disrupt Our Ongoing Business, Distract Our Management, Increase Our Expenses and Adversely Affect Our Business. Our Revenues Could be Affected by Third-Party Reimbursement Policies and Potential Cost Constraints. Increases in Demand for Our Products Could Require Us to Expend Considerable Resources to Meet the Demand or Harm Our Customer Relationships if We are Unable to Meet Demand. Our Failure to Maintain Existing Distribution Channels, or Develop New Distribution Channels, May Result in Lower Revenues. The Use of Sole Supply Sources or Third Party Suppliers For Critical Components of Our Products Could Adversely Affect Our Business. The Unavailability of Certain Products Distributed by a Third Party Could Adversely Affect Sales of Our OraSure Oral Fluid Collection Device. We May Need Strategic Partners to Assist in Developing and Commercializing Some of Our Diagnostic Products. We Have a History of Losses Prior to 2005. Utilization of Our Deferred Tax Assets May Be Limited and is Dependent on Future Taxable Income. We May Require Future Additional Capital. An Economic Downturn, Terrorist Attacks or National Disasters May Adversely Affect Our Business. Our Stock Price Could Continue to be Volatile. Future Sales of Our Common Stock by Existing Stockholders, Executive Officers or Directors Could Depress the Market Price of Our Common Stock and Make It More Difficult For Us to Sell Stock in the Future. Our Reported Financial Results May be Adversely Affected by Changes in Accounting Principles Generally Accepted in the United States. Our Success Depends on Our Ability to Protect Our Proprietary Technology. We are Involved in Pending, and May Become Involved in Future, Intellectual Property Infringement Disputes, Which are Costly and Could Limit or Eliminate Our Ability to Sell Our Products or Use Certain of Our Technologies in the Future. The Sales Potential for OraQuick ADVANCE Could be Affected by Our Ability to Obtain Certain Licenses. A Market for Our Products May Not Develop. If Acceptance and Adoption of Our Oral Fluid Testing Does Not Continue, Our Future Results May Suffer. We May be Sued for Product Liabilities for Injuries Resulting From the Use of Our Products. Performance of Our Products May Affect Our Revenues and Stock Price. Our Increasing International Presence May be Affected by Regulatory, Cultural or Other Restraints.

Full 10-K form ▸

1116463--3/16/2007--ORASURE_TECHNOLOGIES_INC